Skip to main content
Log in

Clostridium-difficile-Kolitis

Ein unterschätztes Problem

Clostridium difficile colitis

An underestimated problem

  • Leitthema
  • Published:
Intensivmedizin und Notfallmedizin

Zusammenfassung

Die häufigste Ursache für antibiotikaassoziierte Diarrhöen ist die Kolitis durch Clostridium difficile. Der Erreger kann leicht nosokomial übertragen werden. Fast jede Antibiotikatherapie ist möglicher Auslöser einer solchen Kolitis. Das Spektrum der Erkrankung reicht von wässrigen Diarrhöen bis hin zu schweren nekrotisierenden Kolitiden mit septischem Verlauf. Schwere Verlaufsformen mit schlechter Prognose sind in den letzten Jahren zunehmend häufiger beschrieben worden. Die Diagnose kann entweder durch den Nachweis des Toxins aus Stuhl, kulturell oder endoskopisch gestellt werden. Die Endoskopie zeigt eine Kolitis mit meist distalem Befall, pathognomonisch ist der Nachweis von Pseudomembranen. Zwei Substanzen stehen zur Therapie zur Verfügung: Metronidazol und Vancomycin. Weitere Substanzen befinden sich in der klinischen Prüfung. Rezidive nach Absetzen der Therapie sind häufig, die Rate kann durch Rekonstitution der Normalflora verringert werden.

Abstract

The most relevant cause of antibiotic therapy-associated diarrhea is Clostridium difficile. C. difficile can readily be transmitted nosocomially and colonize the colon. C. difficile colitis can be caused by almost any antibiotic therapy. The production of toxins leads to colitis with a spectrum ranging from watery diarrhea to necrotizing colitis with a septic course. Severe forms of the disease have been reported with increasing frequency over the last few years. C. difficile colitis can be diagnosed by the typical presentation, combined with detection of toxins in stool specimen, culturally or endoscopically. The typical endoscopic presentation is severe distal colitis with pseudomembranes. Two antibiotic agents are currently licensed for drug therapy of C. difficile colitis: vancomycin and metronidazole. Newer substances are currently in clinical development. Even with successful therapy, recurrent episodes are frequent and require additional therapeutic courses. Reconstitution of normal intestinal flora seems to reduce the rate of recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2

Literatur

  1. Bartlett JG (1994) Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis 18:S265–S272

    PubMed  Google Scholar 

  2. Bauer MP, Kuijper EJ, Dissel JT van (2009) European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium Difficile Infection (CDI). Clin Microbiol Infect 15:1067–1079

    Article  CAS  PubMed  Google Scholar 

  3. Crobach MJ, Dekkers OM, Wilcox MH et al (2009) European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 15:1053–1066

    Article  CAS  PubMed  Google Scholar 

  4. Kuijper EJ, Coignard B, Tull P (2006) Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 12(Suppl 6):2–18

    Article  CAS  PubMed  Google Scholar 

  5. Louie TM, Gerson D, Grimard S et al (2007) Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium Difficile-Associated Diarrhea (CDAD. in 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington DC

  6. Lowy I, Molrine DC, Leav BA et al (2010) Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362:197–205

    Article  CAS  PubMed  Google Scholar 

  7. McDonald LC, Killgore GE, Thompson A et al (2005) An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353:2433–2441

    Article  CAS  PubMed  Google Scholar 

  8. McFarland LV, Mulligan ME, Kwok RY et al (1989) Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320:204–210

    Article  CAS  PubMed  Google Scholar 

  9. McFarland LV, Surawicz CM, Stamm WE (1990) Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 162:678–684

    CAS  PubMed  Google Scholar 

  10. Sullivan KM, Spooner LM (2010) Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection. Ann Pharmacother 44:352–359

    Article  PubMed  CAS  Google Scholar 

  11. Thielman NM, Wilson KH (2009) Antibiotic-associated colitis. In: Mandell GL, Bennett JE, Dolin R (eds) Principles and practices of infectious diseases. Churchill-Livingstone, Philadelphia, pp 1375–1388

  12. Tung JM, Dolovich LR, Lee CH (2009) Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review. Can J Gastroenterol 23:817–821

    PubMed  Google Scholar 

  13. Zar FA, Bakkanagari SR, Moorthi KM et al (2007) A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45:302–307

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

Keine Angaben.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to B. Salzberger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Salzberger, B. Clostridium-difficile-Kolitis. Intensivmed 47, 272–275 (2010). https://doi.org/10.1007/s00390-009-0161-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00390-009-0161-x

Schlüsselwörter

Keywords

Navigation